SCHEDULE: FMR LLC Discloses 6.5% Stake in VOR Biopharma

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.5% beneficial ownership stake in VOR Biopharma Inc. as of December 31, 2025.

Summary

• FMR LLC and its affiliates, including Abigail P. Johnson, beneficially own 2,526,170 shares of VOR Biopharma Inc. common stock.
• This ownership represents 6.5% of VOR Biopharma Inc.'s total outstanding common stock.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• FMR LLC's subsidiaries and affiliates, including FIAM LLC and Fidelity Management & Research Company LLC, are identified as investment advisers.
• Specifically, the Select Biotechnology Portfolio holds 2,522,625 shares, which also constitutes 6.5% of the total outstanding common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial stake by a prominent institutional investor like FMR LLC suggests a vote of confidence in VOR Biopharma's future, even without specific operational details.

Positives

• A significant institutional investment by FMR LLC, a major asset manager, indicates a vote of confidence in VOR Biopharma's long-term prospects.
• The 6.5% stake represents a notable commitment from a reputable financial institution, potentially attracting further investor interest.

Negatives

• The filing itself does not contain any explicit negative information or adverse events related to VOR Biopharma Inc.

Risks

• No specific risks related to VOR Biopharma Inc.'s operations, financial health, or strategic direction are disclosed in this Schedule 13G filing, as it is solely an ownership report.

Industry Context

StockSavvy.ai notes that a significant stake by a major asset manager like FMR LLC in a biopharma company such as VOR Biopharma Inc. can signal institutional confidence in the company's pipeline, market position, or long-term growth potential within the highly competitive biotechnology sector. Such investments often attract attention from other institutional and retail investors, potentially influencing market perception.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not contain performance metrics or operational results that can be directly compared to industry standards or specific comparable companies/projects. The significance lies in the identity and size of the institutional investor rather than a performance benchmark.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC may increase investor confidence and potentially attract further investment, positively impacting share price.
• Company Management: A large institutional holder like FMR LLC may exert influence through voting power, although the filing explicitly states the stake is not for changing control.

Key Dates

Recommendation

While the significant institutional ownership by FMR LLC is a positive indicator of confidence, this Schedule 13G filing provides no operational or financial performance data for VOR Biopharma Inc. to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental disclosures to make a more informed decision.

Keywords

VOR Biopharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Fidelity